Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AbbVie's Juvmo (tavapadon) wins FDA approval as first selective D1/D5 receptor agonist for Parkinson's disease
Small molecule, neurological, dopamine receptor agonist, Parkinson's disease, D1/D5 receptor - Read more

FDA approves Mirum Pharmaceuticals' Atebrioz (zilurgisertib) targeting ALK2 for fibrodysplasia ossificans progressiva based on Ph2 data
Small molecule, musculoskeletal, ALK2 inhibitor, fibrodysplasia ossificans progressiva, rare disease - Read more

Roche's Gazyva (obinutuzumab) wins FDA approval for childhood-onset idiopathic nephrotic syndrome based on Ph3 data
Antibody, autoimmune, monoclonal antibody, nephrotic syndrome, CD20, B cell depletion - Read more

Eli Lilly's Olumiant (baricitinib) wins FDA label expansion for children with severe alopecia areata
Small molecule, autoimmune, JAK inhibitor, alopecia areata, pediatric population - Read more

Grünenthal, DKSH expand Asia-Pacific pain medicine partnership covering four products across eight markets
Commercialization agreement, pain management, small molecule, commercialization - Read more

Merck & Co. licenses SciBrunch Therapeutics' preclinical KRAS inhibitor SPR2015, $400M upfront, up to $2.13B total
Licensing deal, oncology, small molecule, milestone payments - Read more

Tolerance Bio, Tanabe Pharma partner on clinical-stage anti-IL-33 antibody TLB-33, up to $560M milestones
Licensing deal, autoimmune, antibody, milestone payments - Read more

Sun Pharma, LIB Therapeutics partner to commercialize lerodalcibep ex-US and China in $3.7B PCSK9 market
Licensing deal, commercialization, small molecule, cardiovascular, royalties, manufacturing agreement - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Johnson & Johnson's Carvykti (cilta-cel) delivers five-year progression-free remissions in Ph2 relapsed or refractory multiple myeloma
Cell therapy, cancer, CAR-T, multiple myeloma, BCMA target, relapsed or refractory - Read more

Adicet Bio's (prula-cel) achieves lupus remissions in over half of Ph1 patients with favorable safety profile
Cell therapy, autoimmune, CAR-T, lupus, gamma delta T cells, CD19 - Read more

Kodiak Sciences' Zenkuda (tarcocimab tedromer) matches Regeneron's Eylea in Ph3 for wet age-related macular degeneration
Antibody, eye disease, anti-VEGF, wet age-related macular degeneration, monoclonal antibody - Read more

Mirum Pharmaceuticals' (brelovitug) meets Ph3 primary endpoint for chronic hepatitis delta virus treatment
Antibody, infectious disease, monoclonal antibody, hepatitis delta virus, antiviral, hepatitis surface antigen - Read more

Sofinnova Partners raises €82M ($93.3M) fund to expand medtech creation strategy in Europe and U.S.
Medtech, venture capital, life sciences, early-stage - Read more

Scynexis bags $214M BARDA contract to advance antifungal candidate SCY-247 into trials
Infectious disease, antifungal, small molecule, clinical-stage - Read more

StandardX raises £10M ($11.4M) Seed to build scalable isotope refinery for medicine and fusion
Radiopharmaceuticals, cancer, isotope manufacturing, platform technology, nuclear medicine - Read more

Frazier Life Sciences Acquisition II files for $75M IPO, targeting biotech sector investments
Biotech, SPAC, life sciences - Read more

One Biosciences receives €3.3M ($3.8M) non-dilutive grant to advance single-cell precision oncology platform
Oncology, single-cell transcriptomics, AI/ML platform, biomarker discovery, triple-negative breast cancer, diagnostics - Read more

Moyom Biotech raises undisclosed funding from Cathay Capital for regenerative aesthetic biomaterials expansion
Regenerative medicine, biomaterials, medical aesthetics, absorbable implants - Read more

Metagen Therapeutics raises JPY 300M ($1.9M) Series B extension, advancing oral fecal microbiota transplantation drug trials
Microbiome therapeutics, gastrointestinal, ulcerative colitis, Parkinson's disease, clinical-stage - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Roche halts (emugrobart) development after Ph2 failure in obesity/overweight, anti-latent myostatin antibody misses efficacy goals
Antibody, metabolic, monoclonal antibody, obesity, myostatin inhibitor, GLP-1 combination therapy - Read more

Merck & Co., Daiichi Sankyo withdraw accelerated approval bid for (ifinatamab deruxtecan) in extensive-stage small-cell lung cancer
Antibody-drug conjugate, cancer, small-cell lung cancer, B7-H3, accelerated approval - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here